21:34 , May 8, 2019 |  BC Extra  |  Financial News

CRO Viva raises $193.9 million in Hong Kong IPO

Viva will begin trading Thursday after raising HK$1.5 billion (US$193.9 million) early Wednesday in an IPO that values the drug discovery services company at HK$6.6 billion (US$843.1 million). Viva Biotech Holdings (HKSE:1873) sold 345 million...
23:32 , Apr 30, 2019 |  BC Extra  |  Financial News

April 30 Financial Quick Takes: Mustang, Tot Biopharm, Axcella and more

Mustang raises $27.5M after gene therapy data Mustang Bio Inc. (NASDAQ:MBIO) raised $27.5 million in a follow-on underwritten by Cantor Fitzgerald, Oppenheimer, H.C. Wainwright and Roth Capital. The offering comes on the heels of positive...
00:36 , Oct 19, 2018 |  BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
23:48 , Oct 15, 2018 |  BC Extra  |  Company News

Management tracks: Rhythm, Redpin

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) hired Murray Stewart as CMO of the metabolic disorder company. Stewart was CMO of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) until 2017 when he became head of R&D at Novelion Therapeutics Inc. (NASDAQ:NVLN)....
21:33 , Sep 26, 2018 |  BC Extra  |  Company News

Management tracks: Merck clears path for Frazier to remain CEO

The board of Merck & Co. Inc. (NYSE:MRK) rescinded a 28-year-old policy that required CEOs to retire at age 65. CEO Kenneth Frazier, who turns 65 in December 2019, has agreed to stay in his...
06:36 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Tot raises $102M series B

Cancer company Tot Biopharm Co. Ltd. (Suzhou, China) raised $102 million on Aug. 8 in a series B round. Participants included China Universal (Cayman) GP Ltd. and other investors as well as existing investors Center...
06:14 , Aug 10, 2018 |  BC Week In Review  |  Company News

Regeneron, bluebird ink multitarget deal for cancer

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
20:32 , Aug 8, 2018 |  BC Extra  |  Financial News

Tot raises $102M series B

Cancer company Tot Biopharm Co. Ltd. (Suzhou, China) raised $102 million in a series B round. Participants included China Universal (Cayman) GP Ltd. and other investors as well as existing investors Center Laboratories Group, Vivo...
22:43 , Aug 6, 2018 |  BC Extra  |  Company News

Regeneron, bluebird in multitarget cell therapy deal

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
17:58 , Jul 20, 2018 |  BC Week In Review  |  Company News

Kite looks to Gadeta for gamma delta T cell tech

Kite Pharma Inc. and Gadeta B.V. (Utrecht, the Netherlands) partnered to develop T cell therapies that express gamma delta TCRs for hematologic malignancies and solid tumors using Gadeta's platform. Kite, a subsidiary of Gilead Sciences...